Home › Compare › GDIFF vs ABBV
GDIFF yields 7.47% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, GDIFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GDIFF + ABBV for your $10,000?
GDI Integrated Facility Services Inc. operates in the outsourced facility services industry. The company operates through Janitorial Canada, Janitorial USA, and Technical services segments. It offers janitorial services, such as cleaning floors, dusting desks and tables, vacuuming carpets, sanitizing kitchens and washrooms, watering plants, cleaning exterior and interior parking facilities, and removal of garbage, as well as other services, including stripping and waxing floors, carpet cleaning, heavy dust cleaning, and window cleaning. The company also provides mechanical maintenance and electrical services, such as heating, ventilation, and air conditioning services; refrigeration, mechanical and plumbing; cabling and communications; building automation and control; and security systems. In addition, it engages in janitorial products manufacturing and distribution; and sales and distribution of cleaning and sanitation supplies rental and repairs of cleaning equipment. Further, GDI Integrated Facility Services Inc. operates a network of approximately 700 franchises that provide janitorial services to small and medium-size facilities. The company serves office properties, shopping centers, industrial and institutional buildings, educational facilities, health care centers, airports, hospitals, laboratories, national retail stores, and hotels in Canada and the United States. GDI Integrated Facility Services Inc. is headquartered in LaSalle, Canada.
Full GDIFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.